Elevation Oncology, Inc. (ELEV)
| Previous close | 3.6450 |
| Open | 3.6800 |
| Bid | 3.6000 x 100 |
| Ask | 3.6600 x 100 |
| Day's range | 3.5799 - 3.8300 |
| 52-week range | 0.3630 - 5.8900 |
| Volume | |
| Avg. volume | 1,175,841 |
| Market cap | 177.09M |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca
- PR Newswire
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2023, and highlighted recent business achievements.
- PR Newswire
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San
